CurrentBlue Cross Blue Shield - IowaPolicy 05.04.20

Enspryng (satralizumab-mwge) for NMOSD — Coverage Criteria

Defines coverage and prior authorization criteria for Enspryng (satralizumab-mwge) to treat adults with AQP4 antibody‑positive neuromyelitis optica spectrum disorder (NMOSD) for Wellmark/Blue Cross Blue Shield Iowa members.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyEnspryng (satralizumab-mwge) for NMOSD — Coverage Criteria

Policy CodePolicy 05.04.20

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain prior authorization and submit immunoassay documentation confirming anti‑AQP4 antibody positivity.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

AQP4-positive onlyIndication limited to antibody-positive NMOSD

12 monthsApproval duration

2 x 120 mgInitiation quantity limit

1 x 120 mgMaintenance quantity limit

Requires rituximab trialPrior rituximab requirement

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Initial Approval

Covered when ALL of the following are met:

Initial approval criteria: 1) Member is anti‑aquaporin‑4 (AQP4) antibody positive; 2) Medication prescribed by or in consultation with a neurologist; 3) Member exhibits at least one core clinical characteristic of NMOSD: (a) optic neuritis; (b) acute myelitis; (c) area postrema syndrome (episode of otherwise unexplained hiccups or nausea and vomiting); (d) acute brainstem syndrome; (e) symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD‑typical diencephalic MRI lesions; (f) symptomatic cerebral syndrome with NMOSD‑typical brain lesions; 4) History of ≥1 relapse requiring rescue therapy within the previous 12 months prior to initiating therapy; 5) Inadequate response, intolerable adverse event, or documented contraindication to rituximab; 6) Member will not receive Enspryng concomitantly with complement inhibitors (eculizumab, ravulizumab), anti‑CD20 therapy (rituximab), or anti‑CD19 antibody (inebilizumab).

From policy criteria

Continuation Therapy

Covered when ALL of the following are met:

Continuation criteria: Medication prescribed by or in consultation with a neurologist AND member demonstrates positive clinical response from baseline, shown by reduction or maintained reduction in number and/or severity of relapses.

Approval period: 12 months

Contraindications and precautions for Enspryng (satralizumab-mwge) include known hypersensitivity to the drug or any of its active ingredients, active Hepatitis B infection, and active or untreated latent tuberculosis. Administration should be delayed in patients with an active infection. Clinical monitoring is warranted because Enspryng can cause elevated liver enzymes and neutropenia (decreased neutrophil counts)—screening and follow-up labs should be used per standard practice.

The provided reference sections list multiple regulatory and clinical sources but do not specify additional explicit exclusions beyond those stated in the safety/contraindications section. Where procedural or coding exclusions might be needed, they are not detailed in the cited reference chunks.

Clinical trial data demonstrated benefit of Enspryng in the AQP4 antibody–positive population, while the studies showed no evidence of benefit in AQP4 antibody–negative patients; use in that seronegative population therefore does not meet the coverage criteria.

Within the cited reference material there are no standalone statements labeled as ‘not medically necessary’; determinations of medical necessity are tied to whether the member meets the specific coverage criteria described elsewhere in the policy.

Procedure, Billing Codes and Quantity Limits

Provider procedure/billing codesmixed

No codes listed

No codes listed in these sectionsmixed

No codes listed

inv-09: Quantity limits

Initiation quantity limit2 x 120 mg syringes per first 28 days (4 weeks)

Maintenance quantity limit1 x 120 mg syringe per 28 days

Drug formulation referencedEnspryng (satralizumab-mwge) — 120 mg syringe

Prior Authorization, Documentation and Provider Requirements

Prior Authorization

Prior Authorization and Quantity Limits

Prior authorization is required for Enspryng (satralizumab‑mwge). Approval duration is 12 months. Quantity limits: initiation — 2 x 120 mg syringes per first 28 days (4 weeks); maintenance — 1 x 120 mg syringe per 28 days.

Prior authorization required
Approval period: 12 months
Quantity limits: Initiation 2 x 120 mg per first 28 days; Maintenance 1 x 120 mg per 28 days

Denial Risk

Requests for Enspryng — Medical Necessity

Requests for Enspryng will be considered medically necessary only when the member meets the documented clinical criteria (see Initial Approval criteria). Requests will be considered not medically necessary if the member does not meet the specified criteria.

Clinical Background

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune demyelinating disorder of the central nervous system that typically presents with severe relapses such as optic neuritis or transverse myelitis leading to cumulative disability. Enspryng is a humanized monoclonal antibody that targets the interleukin‑6 receptor and is administered subcutaneously on a maintenance schedule; it is FDA‑approved for treatment of adults with NMOSD who are AQP4 antibody positive.

Definitions and Target Population

inv-20: AQP4 antibody positive NMOSD

Approved populationAdults with neuromyelitis optica spectrum disorder (NMOSD) who are anti‑aquaporin‑4 (AQP4) antibody positive

Diagnostic confirmation requiredPositive anti‑AQP4 antibody test (immunoassay) documented in prior authorization submission

PrescriberMedication prescribed by or in consultation with a neurologist

inv-21: Core clinical characteristics of NMOSD

Optic neuritisAcute inflammatory attack of the optic nerve causing vision loss or pain with eye movement

Acute myelitisTransverse myelitis presenting with motor, sensory, or autonomic dysfunction attributable to spinal cord inflammation

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyEnspryng (satralizumab-mwge) for NMOSD — Coverage Criteria

Policy CodePolicy 05.04.20

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain prior authorization and submit immunoassay documentation confirming anti‑AQP4 antibody positivity.

SourceLink

On This Page

Therapy considered medically necessary when Initial Approval criteria are met

Not medically necessary if criteria are not met

Note

Authorization / Denial Triggers

There are no explicit separate authorization or denial triggers beyond the stated coverage criteria and documentation requirements; authorization decisions are made based on meeting the clinical criteria and required documentation.

Authorization/denial determined by whether coverage criteria and documentation are met
No additional explicit triggers listed

Documentation Required

Pre‑initiation Screening and Immunization Guidance

Prior to initiation of Enspryng, screen all individuals for hepatitis B (HBV), tuberculosis (TB), and perform liver transaminase/bilirubin testing. Ensure immunizations are up to date: live or live‑attenuated vaccines should be given at least 4 weeks before starting therapy; non‑live vaccines should be given, whenever possible, at least 2 weeks prior to initiation.

HBV screening required prior to initiation
TB screening required prior to initiation
Liver transaminase/bilirubin testing required prior to initiation
Immunizations: live vaccines ≥4 weeks before therapy; non‑live vaccines ≥2 weeks before when possible

Step Therapy

Step Therapy Requirement

Member must have an inadequate response, intolerance, or documented contraindication to rituximab prior to initiating Enspryng (step therapy requirement).

Step therapy requirement: inadequate response/intolerance/contraindication to rituximab documented

Step Therapy

Absence of Additional Step Therapy Requirements

No additional step therapy requirements beyond the rituximab requirement are described in the policy.

No other step therapy described

Documentation Required

Required Documentation

Required documentation to initiate prior authorization: the immunoassay result confirming anti‑AQP4 antibody positivity. For continuation requests, provide medical records (e.g., chart notes, laboratory tests) demonstrating a positive clinical response or stability compared to baseline.

Immunoassay confirming anti‑AQP4 antibody positive required
For continuation: records showing clinical response or stability from baseline

Note

References and Prescribing Information

FDA and manufacturer prescribing information and pivotal clinical trials are cited in the references and may support authorization decisions. Refer to the FDA prescribing information and listed clinical trials/publications when submitting documentation.

FDA prescribing information and approval materials cited
Key clinical trials and guideline references listed (see References)

Area postrema syndromeEpisodes of otherwise unexplained hiccups or intractable nausea and vomiting

Acute brainstem syndromeBrainstem dysfunction manifesting with appropriate clinical signs (e.g., cranial nerve abnormalities)

Symptomatic narcolepsy/diencephalic syndromeNarcolepsy or acute diencephalic clinical syndrome with NMOSD‑typical diencephalic MRI lesions

Symptomatic cerebral syndromeCerebral syndrome with NMOSD‑typical brain lesions causing focal neurologic deficits

inv-22: NMOSD definition

DefinitionNeuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune, demyelinating CNS disease often presenting with optic neuritis or transverse myelitis and causing severe relapses that produce cumulative disability

Pathophysiology/markerDisease is associated with pathogenic anti‑aquaporin‑4 (AQP4) antibodies in the approved population

Therapeutic contextEnspryng is an IL‑6 receptor–targeting humanized monoclonal antibody administered subcutaneously every 4 weeks and is FDA‑approved for adults who are AQP4 antibody positive